Market Cap 131.47M
Revenue (ttm) 0.00
Net Income (ttm) -39.72M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 17,100
Avg Vol 97,186
Day's Range N/A - N/A
Shares Out 8.97M
Stochastic %K 62%
Beta -0.23
Analysts Strong Sell
Price Target $43.64

Company Profile

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophi...

Industry: Biotechnology
Sector: Healthcare
Phone: 416 847 6898
Address:
1920 Yonge Street, Suite 200, Toronto, Canada
GoforProMIS
GoforProMIS Aug. 19 at 4:17 PM
$PMN CEO Neil Warma attended and presented at Jefferies Healthcare, Oppenheimer CNS and at the Bio International Conference with the opportunity of 1to1 meetings. As the Alzheimer Conference took place on on 12-15 July the 4-6 week NDA analyses by the specialist of pharmaceutical companies should be done. IMO we have 5-12 pharmaceutical companies interested in PMN: Biogen /Eisai due to high Aria of Leqembi. Roche as they lost bn with Gantenerumab and need a solution. $ABBV $BMY $NVS are keen to get into neurology as partnership. Pfizer and Takeda looking for Episelect Platform!
0 · Reply
GoforProMIS
GoforProMIS Aug. 19 at 4:13 PM
$PMN IMO we have 5-12 pharmaceutical companies interested in PMN: $BIIB /Eisai due to high Aria of Leqembi. $RHHVF as the lost bn with Gantenerumab and need a solution. Abbvie, Bristol Myers, Novartis are keen to get into neurology as partnership. $PFE and Takeda looking for Episelect Platform! CEO Neil Warma attended and presented at Jefferies Heathcare, Oppenheimer CNS and at the Bio International Conference with the opportunity of 1to1 meetings. As the Alzheimer Conference took place on on 12-15 July the 4-6 week NDA analyses by the specialist of pharmaceutical companies should be done.
0 · Reply
GoforProMIS
GoforProMIS Aug. 19 at 1:42 PM
$PMN $15,40 MACD Crossover trading Algorithm sets in let’s go
0 · Reply
st165576
st165576 Aug. 18 at 11:29 PM
$PMN showing strong relative strength and holding well above moving averages. PMN could rocket to $100 on good ph 1b results. well worth a punt at $15
0 · Reply
JimmyOcarri
JimmyOcarri Aug. 17 at 9:23 PM
0 · Reply
JimmyOcarri
JimmyOcarri Aug. 17 at 7:34 PM
0 · Reply
BrooklynBermudaLondon
BrooklynBermudaLondon Aug. 17 at 6:56 PM
$PMN “ I updated the PMN search through this morning, August 17, 2026, across ProMIS, the Q2 call/transcript, medical publications, Alzheimer-specific outlets, analyst actions and broader AD biomarker developments. There are several things worth adding to our thesis. The net update is positive. 1. The most important new development is external validation of p-tau217 — today NeurologyLive published a new piece today specifically addressing p-tau217 and its ability to move Alzheimer’s detection/intervention earlier. The clinical argument is increasingly that p-tau217 is not simply another exploratory laboratory marker but an increasingly important measure of early AD biology. More importantly for PMN, new lecanemab data reported within the past week show that p-tau217 falls as early as three months after lecanemab initiation and that the reduction is associated with better subsequent cognitive outcomes. That is directly relevant to something we just discussed.
1 · Reply
BrooklynBermudaLondon
BrooklynBermudaLondon Aug. 17 at 12:22 PM
$PMN an AI analysis of 13F filings “Ignoring warrants entirely, the clean calculation from the latest reported actual common shares is: * Actual PMN common shares outstanding: 8,967,693. This is the company’s reported issued common-share count; it excludes unexercised warrants. * Actual common shares reported by institutions on the latest 13Fs: 7,695,217 from the Fintel data you supplied. (The 7,695,561 figure includes 344 N-PORT shares; economically the difference is immaterial.) * Therefore: 7,695,217 ÷ 8,967,693 = 85.81%. So the answer is 85.8% Approximately 85.8% of PMN’s currently outstanding actual common shares are reported as held by institutions, before considering warrants. That leaves only: 8,967,693 − 7,695,217 = 1,272,476 shares or 14.19% of outstanding common stock, not represented in those institutional 13F positions.”
1 · Reply
GoforProMIS
GoforProMIS Aug. 17 at 8:45 AM
$PMN I bet they will bring it down just to scare retail shareholders
1 · Reply
Towjoe
Towjoe Aug. 16 at 7:00 AM
0 · Reply
Latest News on PMN
ProMIS Neurosciences Earnings Call Transcript: Q2 2026

Aug 13, 2026, 4:30 PM EDT - 5 days ago

ProMIS Neurosciences Earnings Call Transcript: Q2 2026


ProMIS Neurosciences Quarterly report: Q2 2026

Aug 13, 2026, 4:30 PM EDT - 5 days ago

ProMIS Neurosciences Quarterly report: Q2 2026


ProMIS Neurosciences Earnings release: Q2 2026

Aug 13, 2026, 4:30 PM EDT - 5 days ago

ProMIS Neurosciences Earnings release: Q2 2026


ProMIS Neurosciences Transcript: Study result

Jul 28, 2026, 8:00 AM EDT - 22 days ago

ProMIS Neurosciences Transcript: Study result


ProMIS Neurosciences Slides: Study result

Jul 28, 2026, 8:00 AM EDT - 22 days ago

ProMIS Neurosciences Slides: Study result


ProMIS Neurosciences Press release: Study result

Jul 28, 2026, 8:00 AM EDT - 22 days ago

ProMIS Neurosciences Press release: Study result


ProMIS Neurosciences initiated with a Buy at Chardan

2026-07-27T08:20:12.000Z - 23 days ago

ProMIS Neurosciences initiated with a Buy at Chardan


ProMIS Neurosciences initiated with a Buy at Roth Capital

2026-07-08T09:25:08.000Z - 6 weeks ago

ProMIS Neurosciences initiated with a Buy at Roth Capital


ProMIS Neurosciences initiated with a Buy at Roth Capital

2026-07-07T20:10:17.000Z - 6 weeks ago

ProMIS Neurosciences initiated with a Buy at Roth Capital


ProMIS Neurosciences Transcript: AGM 2026

May 20, 2026, 10:30 AM EDT - 3 months ago

ProMIS Neurosciences Transcript: AGM 2026


ProMIS Neurosciences initiated with a Buy at Brookline

2026-05-20T10:26:02.000Z - 3 months ago

ProMIS Neurosciences initiated with a Buy at Brookline


ProMIS Neurosciences Earnings release: Q1 2026

May 12, 2026, 7:00 AM EDT - 3 months ago

ProMIS Neurosciences Earnings release: Q1 2026


ProMIS Neurosciences Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 3 months ago

ProMIS Neurosciences Quarterly report: Q1 2026


ProMIS Neurosciences Slides: Investor presentation

May 11, 2026, 7:00 AM EDT - 3 months ago

ProMIS Neurosciences Slides: Investor presentation


ProMIS Neurosciences Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 4 months ago

ProMIS Neurosciences Proxy statement: Proxy filing


ProMIS Neurosciences Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 4 months ago

ProMIS Neurosciences Proxy statement: Proxy filing


ProMIS Neurosciences files $200M mixed securities shelf

2026-03-25T21:25:26.000Z - 5 months ago

ProMIS Neurosciences files $200M mixed securities shelf


ProMIS Neurosciences Annual report: Q4 2025

Mar 25, 2026, 8:00 AM EDT - 5 months ago

ProMIS Neurosciences Annual report: Q4 2025


ProMIS Neurosciences Earnings release: Q4 2025

Mar 25, 2026, 8:00 AM EDT - 5 months ago

ProMIS Neurosciences Earnings release: Q4 2025


ProMIS Neurosciences Registration statement: Registration filing

Mar 25, 2026, 8:00 AM EDT - 5 months ago

ProMIS Neurosciences Registration statement: Registration filing


ProMIS Neurosciences Registration statement: Registration Filing

Mar 18, 2026, 8:00 AM EDT - 5 months ago

ProMIS Neurosciences Registration statement: Registration Filing


Promis Neurosciences Inc trading resumes

2026-01-30T14:40:46.000Z - 7 months ago

Promis Neurosciences Inc trading resumes


ProMIS Neurosciences exceeds target enrollment in PRECISE-AD

2025-12-18T12:36:07.000Z - 8 months ago

ProMIS Neurosciences exceeds target enrollment in PRECISE-AD


ProMIS Neurosciences announces publication highlighting PMN310

2025-12-10T12:45:11.000Z - 9 months ago

ProMIS Neurosciences announces publication highlighting PMN310


ProMIS Neurosciences Announces Reverse Stock Split

Nov 24, 2025, 8:00 AM EST - 9 months ago

ProMIS Neurosciences Announces Reverse Stock Split


ProMIS Neurosciences Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

ProMIS Neurosciences Earnings release: Q3 2025


ProMIS Neurosciences Quarterly report: Q3 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

ProMIS Neurosciences Quarterly report: Q3 2025


ProMIS Neurosciences Proxy statement: Proxy Filing

Oct 3, 2025, 8:00 AM EDT - 11 months ago

ProMIS Neurosciences Proxy statement: Proxy Filing


ProMIS Neurosciences Proxy statement: Proxy Filing

Oct 3, 2025, 8:00 AM EDT - 11 months ago

ProMIS Neurosciences Proxy statement: Proxy Filing


ProMIS Neurosciences Proxy statement: Proxy Filing

Sep 23, 2025, 8:00 AM EDT - 11 months ago

ProMIS Neurosciences Proxy statement: Proxy Filing


ProMIS Neurosciences Earnings release: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Earnings release: Q2 2025


ProMIS Neurosciences Quarterly report: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Quarterly report: Q2 2025


ProMIS Neurosciences Announces Private Placement Financing

Jul 28, 2025, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Announces Private Placement Financing


ProMIS Neurosciences Quarterly report: Q1 2025

May 12, 2025, 7:30 AM EDT - 1 year ago

ProMIS Neurosciences Quarterly report: Q1 2025


ProMIS Neurosciences Earnings release: Q1 2025

May 12, 2025, 7:30 AM EDT - 1 year ago

ProMIS Neurosciences Earnings release: Q1 2025


ProMIS Neurosciences Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

ProMIS Neurosciences Proxy statement: Proxy Filing


ProMIS Neurosciences Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

ProMIS Neurosciences Proxy statement: Proxy Filing


ProMIS Neurosciences Annual report: Q4 2024

Mar 31, 2025, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Annual report: Q4 2024


ProMIS Neurosciences Earnings release: Q4 2024

Mar 31, 2025, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Earnings release: Q4 2024


ProMIS Neurosciences Issues Letter to Shareholders

Jan 13, 2025, 10:30 AM EST - 1 year ago

ProMIS Neurosciences Issues Letter to Shareholders


ProMIS Neurosciences Quarterly report: Q3 2024

Nov 13, 2024, 6:00 PM EST - 1 year ago

ProMIS Neurosciences Quarterly report: Q3 2024


ProMIS Neurosciences Earnings release: Q3 2024

Nov 13, 2024, 6:00 PM EST - 1 year ago

ProMIS Neurosciences Earnings release: Q3 2024


ProMIS Neurosciences Proxy statement: Proxy Filing

Sep 9, 2024, 8:00 AM EDT - 2 years ago

ProMIS Neurosciences Proxy statement: Proxy Filing


ProMIS Neurosciences Proxy statement: Proxy Filing

Sep 9, 2024, 8:00 AM EDT - 2 years ago

ProMIS Neurosciences Proxy statement: Proxy Filing


ProMIS Neurosciences Proxy statement: Proxy Filing

Aug 29, 2024, 8:00 AM EDT - 2 years ago

ProMIS Neurosciences Proxy statement: Proxy Filing


ProMIS Neurosciences Quarterly report: Q2 2024

Aug 7, 2024, 6:00 PM EDT - 2 years ago

ProMIS Neurosciences Quarterly report: Q2 2024


ProMIS Neurosciences Earnings release: Q2 2024

Aug 7, 2024, 6:00 PM EDT - 2 years ago

ProMIS Neurosciences Earnings release: Q2 2024


ProMIS Neurosciences Quarterly report: Q1 2024

May 13, 2024, 6:00 PM EDT - 2 years ago

ProMIS Neurosciences Quarterly report: Q1 2024


ProMIS Neurosciences Earnings release: Q1 2024

May 13, 2024, 6:00 PM EDT - 2 years ago

ProMIS Neurosciences Earnings release: Q1 2024


ProMIS Neurosciences Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

ProMIS Neurosciences Proxy statement: Proxy Filing


ProMIS Neurosciences Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

ProMIS Neurosciences Proxy statement: Proxy Filing


ProMIS Neurosciences Earnings release: Q4 2023

Mar 31, 2024, 6:00 PM EDT - 2 years ago

ProMIS Neurosciences Earnings release: Q4 2023


ProMIS Neurosciences Annual report: Q4 2023

Mar 31, 2024, 6:00 PM EDT - 2 years ago

ProMIS Neurosciences Annual report: Q4 2023


GoforProMIS
GoforProMIS Aug. 19 at 4:17 PM
$PMN CEO Neil Warma attended and presented at Jefferies Healthcare, Oppenheimer CNS and at the Bio International Conference with the opportunity of 1to1 meetings. As the Alzheimer Conference took place on on 12-15 July the 4-6 week NDA analyses by the specialist of pharmaceutical companies should be done. IMO we have 5-12 pharmaceutical companies interested in PMN: Biogen /Eisai due to high Aria of Leqembi. Roche as they lost bn with Gantenerumab and need a solution. $ABBV $BMY $NVS are keen to get into neurology as partnership. Pfizer and Takeda looking for Episelect Platform!
0 · Reply
GoforProMIS
GoforProMIS Aug. 19 at 4:13 PM
$PMN IMO we have 5-12 pharmaceutical companies interested in PMN: $BIIB /Eisai due to high Aria of Leqembi. $RHHVF as the lost bn with Gantenerumab and need a solution. Abbvie, Bristol Myers, Novartis are keen to get into neurology as partnership. $PFE and Takeda looking for Episelect Platform! CEO Neil Warma attended and presented at Jefferies Heathcare, Oppenheimer CNS and at the Bio International Conference with the opportunity of 1to1 meetings. As the Alzheimer Conference took place on on 12-15 July the 4-6 week NDA analyses by the specialist of pharmaceutical companies should be done.
0 · Reply
GoforProMIS
GoforProMIS Aug. 19 at 1:42 PM
$PMN $15,40 MACD Crossover trading Algorithm sets in let’s go
0 · Reply
st165576
st165576 Aug. 18 at 11:29 PM
$PMN showing strong relative strength and holding well above moving averages. PMN could rocket to $100 on good ph 1b results. well worth a punt at $15
0 · Reply
JimmyOcarri
JimmyOcarri Aug. 17 at 9:23 PM
0 · Reply
JimmyOcarri
JimmyOcarri Aug. 17 at 7:34 PM
0 · Reply
BrooklynBermudaLondon
BrooklynBermudaLondon Aug. 17 at 6:56 PM
$PMN “ I updated the PMN search through this morning, August 17, 2026, across ProMIS, the Q2 call/transcript, medical publications, Alzheimer-specific outlets, analyst actions and broader AD biomarker developments. There are several things worth adding to our thesis. The net update is positive. 1. The most important new development is external validation of p-tau217 — today NeurologyLive published a new piece today specifically addressing p-tau217 and its ability to move Alzheimer’s detection/intervention earlier. The clinical argument is increasingly that p-tau217 is not simply another exploratory laboratory marker but an increasingly important measure of early AD biology. More importantly for PMN, new lecanemab data reported within the past week show that p-tau217 falls as early as three months after lecanemab initiation and that the reduction is associated with better subsequent cognitive outcomes. That is directly relevant to something we just discussed.
1 · Reply
BrooklynBermudaLondon
BrooklynBermudaLondon Aug. 17 at 12:22 PM
$PMN an AI analysis of 13F filings “Ignoring warrants entirely, the clean calculation from the latest reported actual common shares is: * Actual PMN common shares outstanding: 8,967,693. This is the company’s reported issued common-share count; it excludes unexercised warrants. * Actual common shares reported by institutions on the latest 13Fs: 7,695,217 from the Fintel data you supplied. (The 7,695,561 figure includes 344 N-PORT shares; economically the difference is immaterial.) * Therefore: 7,695,217 ÷ 8,967,693 = 85.81%. So the answer is 85.8% Approximately 85.8% of PMN’s currently outstanding actual common shares are reported as held by institutions, before considering warrants. That leaves only: 8,967,693 − 7,695,217 = 1,272,476 shares or 14.19% of outstanding common stock, not represented in those institutional 13F positions.”
1 · Reply
GoforProMIS
GoforProMIS Aug. 17 at 8:45 AM
$PMN I bet they will bring it down just to scare retail shareholders
1 · Reply
Towjoe
Towjoe Aug. 16 at 7:00 AM
0 · Reply
Towjoe
Towjoe Aug. 16 at 6:58 AM
$PMN been a scam from day 1
0 · Reply
Towjoe
Towjoe Aug. 16 at 6:58 AM
0 · Reply
Towjoe
Towjoe Aug. 16 at 6:56 AM
0 · Reply
GoforProMIS
GoforProMIS Aug. 14 at 6:58 PM
$PMN just fyi new PT from Guggenheim raised to $100 Skipping Phase 2: Question of dosage has been resolved. If a 1b trial as PMN310 tests various escalating dose groups 5 mg to max. dose of 20 mg on actual patients, it has already accomplished the primary objective of Phase 2. Exceptional regarding biomarkers: When evidence is mathematically irrefutable—rendering it logically impossible to question the drugs efficacy— FDA no longer requires an artificial interim study. Impeccable safety at the maximum dose, if the DSMB records a 0.0% incidence of severe side effects at the max. dose during the Phase 1b trial, the primary regulatory hurdle is removed. High unmet medical need: FDA accelerates the process for fatal or incurable diseases like Alzheimer’s. If PMN shows the potential to be safer than existing treatments as Lilly Biogen . FDA views it ethical imperative to expedite the approval process through fast-track programs. $NVS $GILD $SNY
0 · Reply
GoforProMIS
GoforProMIS Aug. 14 at 5:26 PM
$PMN new PT from Guggenheim raised to $100 Skipping Phase 2: Question of dosage has been resolved. If a 1b trial as PMN310 tests various escalating dose groups 5 mg to max. dose of 20 mg on actual patients, it has already accomplished the primary objective of Phase 2. Exceptional regarding biomarkers: When evidence is mathematically irrefutable—rendering it logically impossible to question the drugs efficacy— FDA no longer requires an artificial interim study. Impeccable safety at the maximum dose, if the DSMB records a 0.0% incidence of severe side effects at the max. dose during the Phase 1b trial, the primary regulatory hurdle is removed. High unmet medical need: FDA accelerates the process for fatal or incurable diseases like Alzheimer’s. If PMN shows the potential to be safer than existing treatments as Lilly Biogen . FDA views it ethical imperative to expedite the approval process through fast-track programs. $MRK $RHHBY $ABBV
1 · Reply
GoforProMIS
GoforProMIS Aug. 14 at 5:20 PM
$PMN Guggenheim raised PT to $100 Skipping Phase 2: Question of dosage has been resolved. If a 1b trial as PMN310 tests various escalating dose groups 5 mg to max. dose of 20 mg on actual patients, it has already accomplished the primary objective of Phase 2. Exceptional regarding biomarkers: When evidence is mathematically irrefutable—rendering it logically impossible to question the drugs efficacy— FDA no longer requires an artificial interim study. Impeccable safety at the maximum dose, if the DSMB records a 0.0% incidence of severe side effects at the max. dose during the Phase 1b trial, the primary regulatory hurdle is removed. High unmet medical need: FDA accelerates the process for fatal or incurable diseases like Alzheimer’s. If PMN shows the potential to be safer than existing treatments as Lilly Biogen . FDA views it ethical imperative to expedite the approval process through fast-track programs. $PFE $JNJ $BMY
0 · Reply
Q8ha
Q8ha Aug. 14 at 5:18 PM
$PMN After closing the entire week above the 14.5 level, next week will be eventful 🚀 Wait and see
1 · Reply
Fruchtworg
Fruchtworg Aug. 14 at 3:32 PM
$PMN call was good imho imho this is like basically done , just wait and be happy, lovely 😊
0 · Reply
Fruchtworg
Fruchtworg Aug. 14 at 3:20 PM
$POET $IBRX growth friends, if y'all interested in some space action , check out $LUNR it's about where $POET will waltz towards mid/end september and $IBRX around q3 earnings i suppose just look at volume and the usual stuff . imho past inflection -> only stock i currently know of that's more hot in this genre is $PMN 💸🧠👀
0 · Reply
GoforProMIS
GoforProMIS Aug. 14 at 3:14 PM
$PMN so the negotiations are ongoing on the other side slow and steady accumulation too if it breaks $15,30 MACD will cross and then see what happens!
0 · Reply
GoforProMIS
GoforProMIS Aug. 14 at 2:13 PM
$PMN PT Raised to $100 at Guggenheim Skipping Phase 2: Question of dosage has been resolved. If a 1b trial as PMN310 tests various escalating dose groups 5 mg to max. dose of 20 mg on actual patients, it has already accomplished the primary objective of Phase 2. Exceptional regarding biomarkers: When evidence is mathematically irrefutable—rendering it logically impossible to question the drug's efficacy— FDA no longer requires an artificial interim study. Impeccable safety at the maximum dose, if the DSMB records a 0.0% incidence of severe side effects at the max. dose during the Phase 1b trial, the primary regulatory hurdle is removed. High unmet medical need: FDA accelerates the process for fatal or incurable diseases like Alzheimer's. If PMN shows the potential to be safer than existing treatments $LLY $BIIB. FDA views it ethical imperative to expedite the approval process through fast-track programs. https://www.streetinsider.com/dr/news.php?id=26925256&gfv=1
0 · Reply
tonkotsu
tonkotsu Aug. 14 at 1:44 PM
$PMN My overall takeaway from the earnings call is that it really sounds like they are looking for a buyout at the readout in Q1. Doesn’t sound like they’re interested in doing any phase 3 themselves or develop the other stuff in their pipeline. They’re just hoping for a positive results for their Phase 1b and looking for a buyer afterwards.
0 · Reply